Alzamend Neuro
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Alzamend Neuro generated cash of -$8,269,993, which is more than the previous year. Cash used in financing activities reached the amount of $3,652,425 last year. Net change in cash is therefore -$4,764,811.
Cash Flow
| 2017 | -1.41M | 0 | 1.42M |
|---|---|---|---|
| 2019 | -1.04M | 234.08K | 308.72K |
| 2020 | -2.34M | 105K | 2.28M |
| 2021 | -2.71M | 100.91K | 4.45M |
| 2022 | -6.61M | -106.45K | 18.85M |
| 2023 | -8.92M | 0 | 200 |
| 2024 | -8.26M | -147.24K | 3.65M |
ALZN Cash Flow Statement (2017 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 5.14M | 14.06M | 1.92M | 90.28K | 42.60K | 545.00K | 1.14K |
Operating activities | |||||||
Net income | -9.94M | -14.87M | -12.36M | -5.04M | -4.41M | -4.86M | -1.56M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 50.74K | 23.06K | 3.54K | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 955.63K | 3.58M | 4.40M | 2.03M | 1.80M | 396.17K | 114.40K |
| Deferred income tax benefit | 955.63K | 3.58M | 4.40M | 2.03M | 1.80M | 396.17K | 114.40K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 1.70M | 693.58K | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -8.26M | -8.92M | -6.61M | -2.71M | -2.34M | -1.04M | -1.41M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 5.37M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -147.24K | 0 | -106.45K | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -147.24K | 0 | -106.45K | 100.91K | 105K | 234.08K | 0 |
Financing activities | |||||||
Common Stock Issued | 1.25M | 989.33K | 18.91M | 2.1M | 2.28M | 236.02K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 300K | 0 | 0 | -1.91K | -16.8K | 0 | 0 |
Cash used in financing activities | 3.65M | 200 | 18.85M | 4.45M | 2.28M | 308.72K | 1.42M |
Net Change In Cash | -4.76M | -8.92M | 12.13M | 1.83M | 47.67K | -502.39K | 3.83K |
Cash at end of period | 376.04K | 5.14M | 14.06M | 1.92M | 90.28K | 42.60K | 4.97K |
| Data source | Data source | Data source | Data source |